ACAD Acadia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD

Price (delayed)

$18.6

Market cap

$3.02B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.34

Enterprise value

$2.95B

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who ...

Highlights
ACAD's revenue is up by 7% YoY
ACAD's gross profit is up by 7% year-on-year
The quick ratio has declined by 37% year-on-year and by 10% since the previous quarter
The net income has declined by 29% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acadia-pharm.com
Peers: VNDA JNJ PFE BMY

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
162.23M
Market cap
$3.02B
Enterprise value
$2.95B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.52
Price to sales (P/S)
5.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.7
Earnings
Revenue
$517.24M
EBIT
-$213.44M
EBITDA
-$211.42M
Free cash flow
-$114.04M
Per share
EPS
-$1.34
Free cash flow per share
-$0.71
Book value per share
$2.47
Revenue per share
$3.2
TBVPS
$3.64
Balance sheet
Total assets
$587.81M
Total liabilities
$187.4M
Debt
$52.7M
Equity
$400.41M
Working capital
$382.31M
Liquidity
Debt to equity
0.13
Current ratio
4.04
Quick ratio
3.87
Net debt/EBITDA
0.32
Margins
EBITDA margin
-40.9%
Gross margin
98%
Net margin
-41.8%
Operating margin
-43.2%
Efficiency
Return on assets
-35.6%
Return on equity
-50.6%
Return on invested capital
-55.9%
Return on capital employed
-46.2%
Return on sales
-41.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
1.97%
1 week
-5.87%
1 month
-4.12%
1 year
-30.83%
YTD
16.83%
QTD
16.83%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$517.24M
Gross profit
$507.07M
Operating income
-$223.6M
Net income
-$215.98M
Gross margin
98%
Net margin
-41.8%
The operating income has contracted by 31% YoY
The net income has declined by 29% year-on-year
The operating margin has decreased by 23% YoY
The net margin has decreased by 20% YoY

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.52
P/S
5.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.7
The EPS has decreased by 28% YoY
The company's equity fell by 26% YoY and by 6% QoQ
ACAD's price to book (P/B) is 12% higher than its last 4 quarters average of 6.7 but 9% lower than its 5-year quarterly average of 8.3
ACAD's P/S is 52% below its 5-year quarterly average of 12.1 but 3.8% above its last 4 quarters average of 5.6
ACAD's revenue is up by 7% YoY

Efficiency

How efficient is Acadia Pharmaceuticals business performance
The ROE has plunged by 70% YoY and by 7% from the previous quarter
ACAD's return on invested capital has dropped by 59% year-on-year and by 6% since the previous quarter
Acadia Pharmaceuticals's return on assets has shrunk by 53% YoY and by 4.1% QoQ
The ROS has decreased by 19% YoY

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The current ratio has contracted by 37% YoY and by 10% from the previous quarter
The quick ratio has declined by 37% year-on-year and by 10% since the previous quarter
The debt is 87% lower than the equity
The debt to equity has grown by 30% year-on-year
The company's equity fell by 26% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.